Clinical Trial

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 4, 2021 (before its estimated March 3, 2025 completion). Its status may not reflect the trial's current state.
Summary
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that PD-1 treatment added to salvage surgery could further decrease the rate of disease progression and improve the survival outcome of patients with resectable locally recurrent nasopharyngeal carcinoma compared with those treated with salvage surgery alone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-02-28.
Trial Details
NCT Number NCT04778956
Lead Sponsor Sun Yat-sen University
Collaborators: First Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital, Southern Medical University, First People's Hospital of Foshan, Zhongshan People's Hospital, Guangdong, China, Tenth Affiliated Hospital, Sun Yat-sen University
Conditions Nasopharyngeal Carcinoma, PD-1, Surgery
Enrollment 218 participants
Start Date 2021-03-03
Primary Completion 2025-03-03 (estimated)
Study Completion 2033-03-03 (estimated)
Updated on ClinicalTrials.gov 2021-03-04